Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?

(2013) Matteo Santoni et al.   CURRENT CANCER DRUG TARGETS

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

(2012) Daniel C. Cho et al.   CANCER

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

(2012) Brian Rini et al.   CANCER

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

(2012) Peter Mulders et al.   EUROPEAN JOURNAL OF CANCER

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

(2012) Tim Eisen et al.   LANCET ONCOLOGY

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

(2011) John D. Hainsworth et al.   CANCER INVESTIGATION

The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage

(2011) Haiying Wang et al.   DNA REPAIR

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

(2011) Nizar M. Tannir et al.   EUROPEAN JOURNAL OF CANCER

A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

(2011) Derek Shek et al.   International Journal of Clinical Oncology

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

(2011) Didier Roulin et al.   Molecular Cancer

Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib

(2010) T. Powles et al.   ANNALS OF ONCOLOGY

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma

(2010) A Horiguchi et al.   BRITISH JOURNAL OF CANCER

A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathways

(2010) Klaus Podar et al.   CELL CYCLE

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

(2010) Dale R. Shepard et al.   INVESTIGATIONAL NEW DRUGS

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

(2010) J C Welti et al.   ONCOGENE

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib

(2009) Laura Vroling et al.   ANGIOGENESIS

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

(2009) W. P. Tew et al.   CLINICAL CANCER RESEARCH

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma

(2008) V. A. Carroll et al.   CANCER RESEARCH

The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells

(2008) S. Soundararajan et al.   CANCER RESEARCH